18
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Jiedu Sangen Decoction Inhibits the Invasion and Metastasis of Colorectal Cancer Cells by Regulating EMT through the Hippo Signaling Pathway

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Colorectal cancer (CRC) is one of the most common malignant tumors affecting the digestive tract. Moreover, the invasion and metastasis of CRC are the main reason therapy is usually inefficient. Decreased intercellular adhesion and enhanced cell motility induced by epithelial-mesenchymal transition (EMT) provide the basic conditions for the invasion and metastasis of the epithelial tumor cells of CRC. The Jiedu Sangen Decoction (JSD) is a prescription that has been used for more than 50 years in the treatment of CRC in the Zhejiang Hospital of Traditional Chinese Medicine. The aim of this study was to investigate the mechanism of JSD-triggered inhibition of invasion and metastasis in colon cancer. In vitro, the EMT model of the SW480 cells was induced by using epithelial growth factor (50 ng/mL). In vivo, the murine model of liver metastasis was constructed by inoculating mice with the SW480 cells. The effects of JSD on cell migration, invasion, and proliferation were determined using the transwell assay and CCK-8 assay. Moreover, the proteins related to the EMT process and the Hippo signaling pathway in the cancerous tissues and cell lines were determined by western blotting and immunostaining. JSD could significantly inhibit the proliferation, migration, and invasion of CRC cells and reverse their EMT status (all, P < 0.05). Moreover, after intervention with JSD, the levels of E-Cadherin (E-cad) increased, whereas the expression levels of N-Cadherin (N-cad), Yes-associated protein (YAP), and the transcriptional coactivator with the PDZ-binding motif (TAZ) decreased in both the SW480 cells and the tumor tissues. In summary, JSD reversed EMT and inhibited the invasion and metastasis of CRC cells through the Hippo signaling pathway.

          Related collections

          Most cited references28

          • Record: found
          • Abstract: not found
          • Article: not found

          Interplay between YAP/TAZ and Metabolism

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            A time for YAP1: Tumorigenesis, immunosuppression and targeted therapy

            YAP1 is one of the most important effectors of the Hippo pathway and has crosstalk with other cancer promoting pathways. YAP1 contributes to cancer development in various ways that include promoting malignant phenotypes, expansion of cancer stem cells and drug resistance of cancer cells. Because pharmacologic or genetic inhibition of YAP1 suppresses tumor progression and increases the drug sensitivity, targeting YAP1 may open a fertile avenue for a novel therapeutic approach in relevant cancers. Recent enormous studies have established the efficacy of immunotherapy, and several immune checkpoint blockades are in clinical use or in the phase of development to treat various cancer types. Immunosuppression in the tumor microenvironment (TME) induced by cancer cells, immune cells and associated stromal cells promotes tumor progression and causes drug resistance. Accumulated evidences of scientific efforts from the last few years suggest that YAP1 influences macrophages, myeloid-derived suppressor cells and regulatory T-cells to facilitate immunosuppressive TME. Although the underlying mechanisms is not clearly discerned, it is evident that YAP1 activating pathways in different cellular components induce immunosuppressive TME. In this review, we summarize the evidences involved in the dual roles of YAP1 in cancer development and immunosuppression in the TME. We also discuss the possibility of YAP1 as a novel therapeutic target.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              The Hippo pathway in normal development and cancer

                Bookmark

                Author and article information

                Contributors
                Journal
                Evid Based Complement Alternat Med
                Evid Based Complement Alternat Med
                ECAM
                Evidence-based Complementary and Alternative Medicine : eCAM
                Hindawi
                1741-427X
                1741-4288
                2019
                25 June 2019
                25 June 2019
                : 2019
                : 1431726
                Affiliations
                1The First Clinical Medical College of Zhejiang Chinese Medical University, No. 548, Binwen Road, Binjiang District, Hangzhou 310053, Zhejiang, China
                2Department of Traditional Chinese Medicine, The First People's Hospital of Quzhou, No. 2, Zhongloudi Road, Kecheng District, Quzhou 324000, Zhejiang, China
                3Department of Cancer Medicine, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London W12 0HS, UK
                4Department of Medical Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University, No. 54, Youdian Road, Shangcheng District, Hangzhou 310006, Zhejiang, China
                Author notes

                Academic Editor: Victor Kuete

                Author information
                https://orcid.org/0000-0002-6245-9437
                https://orcid.org/0000-0001-5956-1943
                https://orcid.org/0000-0001-7321-3830
                https://orcid.org/0000-0003-1061-5255
                Article
                10.1155/2019/1431726
                6614995
                31341488
                ea5b83b8-0a3f-40e4-b11a-d68001f0265e
                Copyright © 2019 Li Yuan et al.

                This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 11 April 2019
                : 13 June 2019
                Funding
                Funded by: Natural Science Foundation of Zhejiang Province
                Award ID: LQ17H290002
                Award ID: LY17H270007
                Funded by: Zhejiang Provincial TCM Scientific Research Fund Project
                Award ID: 2019ZQ015
                Award ID: 2017ZA048
                Funded by: National Natural Science Foundation of China
                Award ID: 81573902
                Funded by: Zhejiang Provincial Medical and Health Science and Technology Project
                Award ID: 2017KY119
                Funded by: China Postdoctoral Science Foundation
                Award ID: 2017M612040
                Award ID: 2018T110610
                Categories
                Research Article

                Complementary & Alternative medicine
                Complementary & Alternative medicine

                Comments

                Comment on this article